risedronic acid has been researched along with Menopause in 5 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 9.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 5.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, CW | 1 |
| Lim, SJ | 1 |
| Moon, YW | 1 |
| Choi, SH | 1 |
| Shin, MH | 1 |
| Min, YK | 1 |
| Yoon, BK | 1 |
| Park, YS | 1 |
| Hirschmann, S | 1 |
| Gibel, A | 1 |
| Tsvelikhovsky, I | 1 |
| Lisker, A | 1 |
| Ruffoni, D | 1 |
| Fratzl, P | 1 |
| Roschger, P | 1 |
| Phipps, R | 1 |
| Klaushofer, K | 1 |
| Weinkamer, R | 1 |
| Lai, PS | 1 |
| Chua, SS | 1 |
| Chew, YY | 1 |
| Chan, SP | 1 |
| Roux, C | 1 |
| Reid, DM | 1 |
| Devogelaer, JP | 1 |
| Saag, K | 1 |
| Lau, CS | 1 |
| Reginster, JY | 1 |
| Papanastasiou, P | 1 |
| Bucci-Rechtweg, C | 1 |
| Su, G | 1 |
| Sambrook, PN | 1 |
3 trials available for risedronic acid and Menopause
| Article | Year |
|---|---|
Fracture recurrence in hip fracture with menopausal hormone therapy versus risedronate: a clinical trial.
Topics: Hip Fractures; Hormone Replacement Therapy; Humans; Menopause; Risedronic Acid | 2021 |
Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Topics: Alendronate; Biomarkers, Pharmacological; Bone and Bones; Bone Density; Bone Density Conservation Ag | 2011 |
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone De | 2012 |
2 other studies available for risedronic acid and Menopause
| Article | Year |
|---|---|
Late-onset psychosis and risedronate treatment for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Male; Menopause; Middle Aged; Osteop | 2015 |
Effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study.
Topics: Bone and Bones; Bone Density; Bone Remodeling; Computer Simulation; Etidronic Acid; Female; Humans; | 2008 |